Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature. (2022). Biomolecules and Biomedicine, 22(2), 300-301. https://doi.org/10.17305/bjbms.2021.6419